AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8408500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (100 mg orally, two doses: 24 and 12 hours before vacuum aspiration)
Number of subjects: 38
Study 8408500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (100 mg orally, two doses: 48 and 36 hours before vacuum aspiration)
Number of subjects: 38
Study 8408500 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two doses, timing as per respective groups)
Number of subjects: 38
Study 3888430 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 30
Study 3888430 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 30
Study 29921144 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIT-ED (Parent-Child Interaction Therapy with Emotion Development module)
Number of subjects: 229
Study 29921144 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (Control)
Number of subjects: 229
Study 29921144 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIT-ED
Number of subjects: 229
Study 27460780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangshen Formula (TSF)
Number of subjects: 180
Study 27460780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 24829362 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (cTnI) concentrations
Number of subjects: 253
Study 24829362 — intervention group
Group type: EXPERIMENTAL
Intervention: Indexed left ventricular (LV) mass and measures of replacement fibrosis (late gadolinium enhancement)
Number of subjects: 253
Study 24829362 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 253
Study 21988525 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary programme (specifics not provided)
Number of subjects: 214
Study 21988525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 214
Study 21988525 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural‐oriented Physiotherapy (PT)
Number of subjects: 214
Study 21988525 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Medicine Rehabilitation (BM)
Number of subjects: 214
Study 21988525 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (CG)
Number of subjects: 214
Study 20195472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPTp) with sulphadoxine‐pyrimethamine (SP)
Number of subjects: 1030
Study 20195472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030
Study 18479285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine extended release (ER)
Number of subjects: 863
Study 15753115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization
Number of subjects: 813
Study 15753115 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 813
Study 12412687 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum pressure support ventilator
Number of subjects: 10
Study 12412687 — intervention group
Group type: COMPARATOR
Intervention: Sullivan variable positive airway pressure II ST
Number of subjects: 10
Study 10490440 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar disinfected water
Number of subjects: 349
Study 10490440 — intervention group
Group type: COMPARATOR
Intervention: Control (indoor water)
Number of subjects: 349
Study 7569737 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mgI ml‐1
Number of subjects: 16
Study 7569737 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 350 mgI ml‐1
Number of subjects: 16
Study 2007848 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine insulin
Number of subjects: 0
Study 2007848 — intervention group
Group type: COMPARATOR
Intervention: Semisynthetic human insulin
Number of subjects: 0
Study 6138377 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 6
Study 6138377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31274827 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM XT
Number of subjects: 150
Study 31274827 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT)
Number of subjects: 150
Study 31274827 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Operation Forces Tactical Tourniquet (SOFT‐T)
Number of subjects: 150
Study 31274827 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous experience
Number of subjects: 150
Study 31274827 — intervention group
Group type: COMPARATOR
Intervention: First-time users
Number of subjects: 150
Study 28382892 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS), 20 g sachet given from 6 to 18 months
Number of subjects: 728
Study 28382892 — intervention group
Group type: COMPARATOR
Intervention: Control group (IFA and MMN combined), no supplementation
Number of subjects: 728
Study 26529126 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad spectrum antibiotic treatment
Number of subjects: 94
Study 26529126 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic treatment
Number of subjects: 94
Study 24692325 — intervention group
Group type: EXPERIMENTAL
Intervention: traditional NSAIDs (tNSAIDs)
Number of subjects: 0
Study 24692325 — intervention group
Group type: EXPERIMENTAL
Intervention: traditional NSAIDs (tNSAIDs) for longer than 365 days
Number of subjects: 0
Study 24692325 — intervention group
Group type: EXPERIMENTAL
Intervention: traditional NSAIDs (tNSAIDs) combined with high cardiovascular risk
Number of subjects: 0
Study 24692325 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen
Number of subjects: 0
Study 24692325 — intervention group
Group type: EXPERIMENTAL
Intervention: aceclofenac
Number of subjects: 0
Study 24692325 — intervention group
Group type: COMPARATOR
Intervention: low-dose aspirin
Number of subjects: 0
Study 24692325 — intervention group
Group type: EXPERIMENTAL
Intervention: paracetamol
Number of subjects: 0
Study 24692325 — intervention group
Group type: EXPERIMENTAL
Intervention: metamizole
Number of subjects: 0
Study 24692325 — intervention group
Group type: EXPERIMENTAL
Intervention: SYSADOAs
Number of subjects: 0
Study 22744638 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatogastrostomy (PG)
Number of subjects: 116
Study 22744638 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticojejunostomy (PJ)
Number of subjects: 116
Study 19388508 — intervention group
Group type: EXPERIMENTAL
Intervention: Preload/Coload (10 mL/kg before and 10 mL/kg after SAB)
Number of subjects: 87
Study 19388508 — intervention group
Group type: COMPARATOR
Intervention: Preload (20 mL/kg crystalloid infusion before SAB)
Number of subjects: 87
Study 17617272 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir-ritonavir 600/100 mg twice daily
Number of subjects: 595
Study 17617272 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir-ritonavir 400/100 mg twice daily
Number of subjects: 595
Study 16371894 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 40
Study 16371894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12431044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate .025%
Number of subjects: 56
Study 12431044 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium 4%
Number of subjects: 56
Study 10334150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide inhalation solution 0.02% (qid)
Number of subjects: 36
Study 10334150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7486611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrorphan HCl (Ro 01‐6794/706) administered as a loading dose of 200 mg/hr or greater
Number of subjects: 0
Study 7486611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrorphan HCl (Ro 01‐6794/706) administered as a loading dose below 200 mg/hr
Number of subjects: 0
Study 7486611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrorphan HCl (Ro 01‐6794/706) maintenance dose rate between 50‐90 mg/hr for 24 hours
Number of subjects: 0
Study 2044394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (40 mg, 3 times daily)
Number of subjects: 31
Study 2044394 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to Ginkgo biloba extract)
Number of subjects: 31
Study 6272566 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse Canadian Red Spring Wheat bran
Number of subjects: 0
Study 6272566 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse French Soft Wheat bran
Number of subjects: 0
Study 6272566 — intervention group
Group type: COMPARATOR
Intervention: Fine Canadian Red Spring Wheat bran
Number of subjects: 0
Study 6272566 — intervention group
Group type: COMPARATOR
Intervention: Fine French Soft Wheat bran
Number of subjects: 0
Study 31229618 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-friendly Health Recovery Program (CHRP-BB)
Number of subjects: 0
Study 31229618 — intervention group
Group type: COMPARATOR
Intervention: Time-and-attention matched control condition
Number of subjects: 0
Study 28670117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary beetroot juice (BR) - 2×70 mL twice daily, each containing 300 mg nitrate
Number of subjects: 15
Study 28670117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary beetroot juice (BR)
Number of subjects: 15
Study 28670117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) - 2×70 mL twice daily, nitrate-negligible
Number of subjects: 15
Study 28670117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study 25315856 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 121
Study 25315856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 23866851 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 2016
Study 23866851 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 2016
Study 23866851 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR
Number of subjects: 2016
Study 23866851 — intervention group
Group type: COMPARATOR
Intervention: Brain imaging sub-study
Number of subjects: 2016
Study 21606530 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines
Number of subjects: 401
Study 21606530 — intervention group
Group type: EXPERIMENTAL
Intervention: A/H5N1 vaccine
Number of subjects: 401
Study 21606530 — intervention group
Group type: EXPERIMENTAL
Intervention: Solicited local and systemic adverse events
Number of subjects: 401
Study 20178210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic power toothbrush
Number of subjects: 171
Study 20178210 — intervention group
Group type: COMPARATOR
Intervention: Rotation/oscillation power toothbrush
Number of subjects: 171
Study 20178210 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 171
Study 30232958 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of salbutamol/ambroxol fixed-dose combination granules
Number of subjects: 12
Study 30232958 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of salbutamol/ambroxol fixed-dose combination granules
Number of subjects: 12
Study 12940388 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisession, small-group experimental condition encouraging peer outreach
Number of subjects: 250
Study 12940388 — intervention group
Group type: COMPARATOR
Intervention: Equal-attention control condition
Number of subjects: 250
Study 10708006 — intervention group
Group type: EXPERIMENTAL
Intervention: CPRV (n = 114)
Number of subjects: 363
Study 10708006 — intervention group
Group type: COMPARATOR
Intervention: PVRV (n = 117)
Number of subjects: 363
Study 10708006 — intervention group
Group type: EXPERIMENTAL
Intervention: CPRV (n = 132)
Number of subjects: 363
Study 9085961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal (I.T.) clonidine 1 microg/kg
Number of subjects: 20
Study 9085961 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (I.V.) clonidine 4 microg/kg
Number of subjects: 20
Study 8227762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment for affective disorders
Number of subjects: 0
Study 3860660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-brushing only
Number of subjects: 3
Study 3860660 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture-brushing only
Number of subjects: 3
Study 3860660 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 29792202 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message programme in addition to standard care
Number of subjects: 710
Study 29792202 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 710
Study 27592594 — intervention group
Group type: COMPARATOR
Intervention: Daily reminder
Number of subjects: 270
Study 27592594 — intervention group
Group type: COMPARATOR
Intervention: Daily lottery-based incentive
Number of subjects: 270
Study 27592594 — intervention group
Group type: COMPARATOR
Intervention: Combination of daily lottery-based incentive and reminders
Number of subjects: 270
Study 27592594 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 270
Study 25623564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide (5 µg) via Respimat, once daily for 48 weeks
Number of subjects: 338
Study 25623564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 23379112 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatoplasty combined tympanostomy tube surgery
Number of subjects: 2
Study 23379112 — intervention group
Group type: COMPARATOR
Intervention: Palatoplasty only
Number of subjects: 2
Study 20635409 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosomy X restricted to the left ventricle in patients with HLHS
Number of subjects: 19
Study 20635409 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (chromosomally normal pediatric patients with restrictive or dilated cardiomyopathy)
Number of subjects: 19
Study 18505669 — intervention group
Group type: COMPARATOR
Intervention: Primary care treatment
Number of subjects: 568
Study 18505669 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital treatment
Number of subjects: 568
Study 18505669 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 568
Study 16150917 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY(3‐36) (0.4 pmol/kg.min) + GLP‐1(7‐36) (0.4 pmol/kg.min)
Number of subjects: 10
Study 16150917 — intervention group
Group type: COMPARATOR
Intervention: GLP‐1(7‐36) (0.4 pmol/kg.min)
Number of subjects: 10
Study 16150917 — intervention group
Group type: COMPARATOR
Intervention: PYY(3‐36) (0.4 pmol/kg.min)
Number of subjects: 10
Study 16150917 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 16150917 — intervention group
Group type: COMPARATOR
Intervention: High-dose PYY(3‐36) (100 nmol/kg)
Number of subjects: 10
Study 16150917 — intervention group
Group type: COMPARATOR
Intervention: High-dose GLP‐1(7‐36) (100 nmol/kg)
Number of subjects: 10
Study 16150917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose PYY(3‐36) (1 nmol/kg) + GLP‐1(7‐36) (10 nmol/kg)
Number of subjects: 10
Study 16150917 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration in ob/ob and db/db mice
Number of subjects: 10
Study 12543927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine-induced hypochlorhydria
Number of subjects: 16
Study 12543927 — intervention group
Group type: COMPARATOR
Intervention: Normal gastric acidity
Number of subjects: 16
Study 10870749 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pain scales used in clinical trials
Number of subjects: 0
Study 10870749 — intervention group
Group type: COMPARATOR
Intervention: Standard pain scales
Number of subjects: 0
Study 8639012 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse atherosclerosis present in 525 (21%) of participants.
Number of subjects: 2531
Study 8639012 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with diffuse atherosclerosis include increased age, being unmarried, being retired, having less than a high school education, increased alcohol use, hypertension, cigarette smoking, and diabetes.
Number of subjects: 2531
Study 1814742 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated potassium chloride tablet (MET)
Number of subjects: 12
Study 1814742 — intervention group
Group type: COMPARATOR
Intervention: Potassium chloride solution (PS)
Number of subjects: 12
Study 1814742 — intervention group
Group type: COMPARATOR
Intervention: Potassium chloride wax-matrix tablets (WMT)
Number of subjects: 12
Study 6235834 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50-200 mg daily)
Number of subjects: 36
Study 6235834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30591065 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dieting consultations (7 sessions)
Number of subjects: 0
Study 27733250 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) diet for 24 hours
Number of subjects: 38
Study 27733250 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) breakfast
Number of subjects: 38
Study 27733250 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) diet after an overnight fast
Number of subjects: 38
Study 27733250 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) diet after returning to control diet
Number of subjects: 38
Study 27733250 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CARB) diet for 24 hours
Number of subjects: 38
Study 24118040 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 840
Study 24118040 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-containing LNS
Number of subjects: 840
Study 24118040 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-containing LNS
Number of subjects: 840
Study 24118040 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn-soy blend (CSB)
Number of subjects: 840
Study 22443427 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar (2.5 mg daily)
Number of subjects: 26449
Study 22443427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26449
Study 20391891 — intervention group
Group type: EXPERIMENTAL
Intervention: High resistance exercise (n = 20)
Number of subjects: 43
Study 20391891 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 23)
Number of subjects: 43
Study 18030518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-neoadjuvant chemotherapy (NACT) with silver wire markers for tumor margins
Number of subjects: 40
Study 18030518 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-NACT wide local excision (WLE) incorporating pre-NACT margins
Number of subjects: 40
Study 18030518 — intervention group
Group type: COMPARATOR
Intervention: Post-NACT margins used to guide WLE
Number of subjects: 40
Study 15915833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 7
Study 15915833 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 7
Study 11988148 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with latex (active treatment)
Number of subjects: 20
Study 11988148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 10367539 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2/week intravenously diluted in 250 cc of normal saline as 20 minutes infusion for 3 consecutive weeks followed by a 1 week rest period
Number of subjects: 24
Study 10367539 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2/week
Number of subjects: 24
Study 8731874 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 24
Study 8731874 — intervention group
Group type: COMPARATOR
Intervention: Operative treatment
Number of subjects: 24
Study 1856249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric maltol (10 mg)
Number of subjects: 21
Study 1856249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric maltol (60 mg elemental iron as tablets)
Number of subjects: 21
Study 1856249 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate (equivalent dose)
Number of subjects: 21
Study 7024580 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfamethoxazole-trimethoprim
Number of subjects: 35
Study 7024580 — intervention group
Group type: EXPERIMENTAL
Intervention: streptomycin
Number of subjects: 35
Study 7024580 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfisoxazole
Number of subjects: 35
Study 7024580 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfisoxazole and tetracycline
Number of subjects: 35
Study 31476782 — intervention group
Group type: COMPARATOR
Intervention: PLAC+SIE
Number of subjects: 12
Study 31476782 — intervention group
Group type: EXPERIMENTAL
Intervention: AHM+SIE
Number of subjects: 12
Study 31476782 — intervention group
Group type: COMPARATOR
Intervention: PLAC
Number of subjects: 12
Study 28864708 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnosine (2 g daily in two divided doses)
Number of subjects: 50
Study 28864708 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 50
Study 25467171 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive task-oriented training on a supplementary tilt table (EG2)
Number of subjects: 30
Study 25467171 — intervention group
Group type: EXPERIMENTAL
Intervention: Only the affected side knee belt of the tilt table was fastened and progressive task-oriented training was performed using the less-affected lower extremity (EG2)
Number of subjects: 30
Study 25467171 — intervention group
Group type: EXPERIMENTAL
Intervention: Only the affected side knee belt of the tilt table was fastened and one-leg standing training was performed using the less-affected lower extremity (EG1)
Number of subjects: 30
Study 25467171 — intervention group
Group type: COMPARATOR
Intervention: Both knee belts of the tilt table were fastened (CG)
Number of subjects: 30
Study 23722974 — intervention group
Group type: EXPERIMENTAL
Intervention: HRC monitoring
Number of subjects: 97
Study 21426620 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (children read stories enriched with emotional lexicon and participated in conversational language games)
Number of subjects: 100